Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an update.
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, has had its new drug application for Semaglutide Injection accepted by the National Medical Products Administration. This development marks a significant milestone in the company’s R&D efforts in diabetes treatment, potentially enhancing its competitive position in the market. With diabetes being a major focus area, the acceptance of Semaglutide Injection, a GLP-1 receptor agonist, underscores Huisheng’s commitment to expanding its diabetes treatment portfolio and addressing the growing diabetes prevalence in China.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an international company specializing in medical aesthetics and pharmaceuticals. With a focus on innovation, it boasts a strong R&D platform, a diverse global product pipeline, and efficient production capabilities. Huisheng Biopharmaceutical, a subsidiary, is dedicated to diabetes treatment, offering a comprehensive range of products and integrated solutions for diabetic patients.
Average Trading Volume: 135,457,290
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.16B
See more data about 0460 stock on TipRanks’ Stock Analysis page.